ASX:BIT Biotron Limited is engaged in the research, development, and commercialization of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1, and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.
Bullish Outlook:
- If Daily Resistance fails I have a Golden Pocket Target after Identifying previous Breakout Cycles
- Bullish Breakout from long-term downtrend
- FIB Retracement Golden Pocket 0.5-0.618 has been previously respected
- RSI Passed the 50.00 level and is now Bullish
- MACD Bullish Cross
"DISCLAIMER: NO ADVICE. The information presented here is general in nature and is for education purposes only. Nothing should be considered to be advice. You should consult with an appropriate professional for specific advice tailored to your situation."
Bullish Outlook:
- If Daily Resistance fails I have a Golden Pocket Target after Identifying previous Breakout Cycles
- Bullish Breakout from long-term downtrend
- FIB Retracement Golden Pocket 0.5-0.618 has been previously respected
- RSI Passed the 50.00 level and is now Bullish
- MACD Bullish Cross
"DISCLAIMER: NO ADVICE. The information presented here is general in nature and is for education purposes only. Nothing should be considered to be advice. You should consult with an appropriate professional for specific advice tailored to your situation."
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供，也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。